Amgen (NASDAQ:AMGN) Releases Earnings Results, Beats Expectations By $0.53 EPS

Amgen (NASDAQ:AMGN) announced its quarterly earnings results on Tuesday. The medical research company reported $5.29 EPS for the quarter, beating the consensus estimate of $4.76 by $0.53, FiscalAI reports. Amgen had a net margin of 19.47% and a return on equity of 162.59%. The company had revenue of $9.87 billion for the quarter, compared to analyst estimates of $9.46 billion. During the same quarter last year, the business earned $5.31 earnings per share. Amgen’s revenue was up 8.6% compared to the same quarter last year. Amgen updated its FY 2026 guidance to 21.600-23.000 EPS.

Here are the key takeaways from Amgen’s conference call:

• Amgen reported double?digit revenue and EPS growth in 2025, with 14 blockbusters and 18 record products, and provided 2026 guidance of $37.0B–$38.4B in revenue and $21.60–$23.00 non?GAAP EPS, supported by $8.1B free cash flow and ongoing capital returns.
• MariTide is advancing rapidly with six global Phase 3 trials (weight management, T2D, sleep apnea, ASCVD, heart failure), fully enrolled chronic weight studies, and data supporting potential monthly or less?frequent dosing that management calls “paradigm?changing.”
• The Phase 3 VISSCELIA?CV data for Repatha showed a 25% reduction in first major cardiovascular events and a 36% reduction in heart attack, strengthening its position for earlier use (primary prevention) and supporting commercial initiatives like Amgen Now to improve access.
• Biosimilars and oncology remain growth engines — the biosimilars franchise generated $3B in 2025 (>$13B since 2018) and the innovative oncology portfolio (including Imdelltra) grew 11% to $8.7B, with Imdelltra achieving full approval and rapid adoption in small cell lung cancer.
• The FDA requested a voluntary withdrawal of Tavneos following concerns about ChemoCentryx’s readjudication process for nine patients in the pivotal trial; Amgen is in discussions with the agency, creating regulatory uncertainty for that product.

Amgen Price Performance

Shares of AMGN traded down $6.09 during mid-day trading on Tuesday, hitting $338.59. 4,037,196 shares of the company traded hands, compared to its average volume of 2,768,512. The company has a current ratio of 1.28, a quick ratio of 0.99 and a debt-to-equity ratio of 5.45. The stock has a market capitalization of $182.32 billion, a price-to-earnings ratio of 26.17, a PEG ratio of 3.02 and a beta of 0.46. The business has a 50-day moving average of $332.81 and a 200 day moving average of $309.74. Amgen has a one year low of $261.43 and a one year high of $353.25.

Amgen Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, February 13th will be issued a $2.52 dividend. This is a positive change from Amgen’s previous quarterly dividend of $2.38. This represents a $10.08 dividend on an annualized basis and a dividend yield of 3.0%. The ex-dividend date of this dividend is Friday, February 13th. Amgen’s dividend payout ratio (DPR) is presently 73.57%.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the stock. Argus boosted their target price on Amgen from $310.00 to $360.00 and gave the stock a “buy” rating in a report on Tuesday, December 30th. Wall Street Zen raised shares of Amgen from a “buy” rating to a “strong-buy” rating in a report on Monday, December 15th. Oppenheimer set a $400.00 target price on shares of Amgen and gave the stock an “outperform” rating in a report on Thursday, January 29th. UBS Group boosted their target price on shares of Amgen from $380.00 to $390.00 and gave the stock a “buy” rating in a research report on Monday, January 26th. Finally, Truist Financial raised their price target on Amgen from $318.00 to $319.00 and gave the company a “hold” rating in a research report on Thursday, January 8th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Amgen has an average rating of “Moderate Buy” and a consensus price target of $342.45.

Insider Transactions at Amgen

In other Amgen news, SVP Rachna Khosla sold 890 shares of the firm’s stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $336.24, for a total transaction of $299,253.60. Following the sale, the senior vice president directly owned 7,082 shares in the company, valued at approximately $2,381,251.68. This trade represents a 11.16% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP Nancy A. Grygiel sold 3,139 shares of the firm’s stock in a transaction on Thursday, November 20th. The stock was sold at an average price of $337.26, for a total transaction of $1,058,659.14. Following the sale, the senior vice president owned 7,225 shares in the company, valued at approximately $2,436,703.50. The trade was a 30.29% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 10,908 shares of company stock worth $3,674,966 in the last quarter. 0.69% of the stock is owned by company insiders.

Institutional Trading of Amgen

Several institutional investors and hedge funds have recently added to or reduced their stakes in AMGN. Centaurus Financial Inc. lifted its position in Amgen by 66.0% during the third quarter. Centaurus Financial Inc. now owns 1,630 shares of the medical research company’s stock worth $460,000 after purchasing an additional 648 shares during the period. Caitong International Asset Management Co. Ltd lifted its stake in Amgen by 435.8% during the third quarter. Caitong International Asset Management Co. Ltd now owns 284 shares of the medical research company’s stock worth $80,000 after purchasing an additional 231 shares during the last quarter. Advisory Services Network LLC boosted its holdings in shares of Amgen by 6.0% in the 3rd quarter. Advisory Services Network LLC now owns 33,551 shares of the medical research company’s stock valued at $9,468,000 after purchasing an additional 1,903 shares in the last quarter. San Luis Wealth Advisors LLC increased its stake in shares of Amgen by 76.6% in the 3rd quarter. San Luis Wealth Advisors LLC now owns 1,694 shares of the medical research company’s stock valued at $478,000 after purchasing an additional 735 shares during the last quarter. Finally, Apexium Financial LP raised its holdings in shares of Amgen by 1.6% during the 3rd quarter. Apexium Financial LP now owns 2,582 shares of the medical research company’s stock worth $729,000 after buying an additional 40 shares in the last quarter. 76.50% of the stock is owned by institutional investors.

Amgen News Roundup

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Q4 earnings and revenue beat consensus: Amgen reported EPS of $5.29 and revenue of $9.87B, topping estimates and showing a healthy net margin; results were driven by higher drug sales and a lower tax rate. Zacks: AMGN Q4 Beats Reuters: Q4 beat on sales, lower tax rate
• Positive Sentiment: Analyst/media tone: high?profile bullish comments (e.g., Jim Cramer noting a strong pipeline after JPMorgan) support longer?term investor confidence. InsiderMonkey: Cramer on AMGN
• Neutral Sentiment: Company materials and call available for due diligence — press release, slide deck and conference call were posted (useful for assessing drivers by product and geography). Slide deck / press release
• Neutral Sentiment: Reported short?interest data in the morning feeds shows zero shares (likely erroneous or unrevealing) — not a meaningful signal for today’s move.
• Negative Sentiment: FY?2026 guidance disappointed some investors: Amgen set EPS guidance of $21.60–$23.00 (consensus ~22.02), a wide range with a midpoint slightly below consensus; revenue guidance ($37.0B–$38.4B) was in line but not clearly upside. That guidance likely trimmed upside after the earnings beat. MarketBeat: AMGN earnings & guidance
• Negative Sentiment: Recent corporate moves (discussion of ending certain collaborations) and valuation reassessments have prompted analysts to re-examine Amgen’s pipeline economics, adding near?term uncertainty. Yahoo Finance: valuation after collaboration end

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.